CYD-TDV
AXP000206.1 · Vaccine
- Platform
- chimeric yellow fever 17D-dengue virus (ChimeriVax, tetravalent)
- Targets
- DENV-1 prM/E; DENV-2 prM/E; DENV-3 prM/E; DENV-4 prM/E
- Originator
- Mahidol University / Sanofi Pasteur
- Sponsor
- Sanofi Pasteur
Names
| Name | Type | Source |
|---|---|---|
| CYD-TDV | preferred name, code | curator, curator |
| Dengvaxia | brand | curator |
| Dengue Tetravalent Vaccine, Live ambiguous | synonym | fda |
Virus
- Role
- Vaccine vector
- Family
- Flaviviridae
- Virus
- yellow fever virus (NCBI Taxonomy 11089)
- Strain
- 17D-204 backbone (CYD-1 to CYD-4 chimeras)
- Replication
- replicating
- Modifications
- prM and E genes of YF 17D-204 replaced by those of dengue virus serotypes 1, 2, 3 and 4 in four chimeric viruses
- Transgenes
- DENV-1 prM/E, DENV-2 prM/E, DENV-3 prM/E, DENV-4 prM/E
- Route
- subcutaneous
- Source
- evidence
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| EMA | EU | 2018-12-12 | approved | Dengvaxia | Prevention of dengue disease caused by serotypes 1-4 in people aged 6-45 with confirmed previous dengue infection | source |
| FDA | US | 2019-05-01 | approved | Dengvaxia | Prevention of dengue disease caused by serotypes 1-4 in people with laboratory-confirmed previous dengue infection living in endemic areas | source |
| EMA | EU | 2025-10-21 | withdrawn | Dengvaxia | Authorisation withdrawn at the holder's request; marketing permanently stopped for commercial reasons | source |
Clinical trials (10)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT04486638 | Dengvaxia US Pregnancy Registry | Recruiting | 2023-01-01 | 2029-06-30 | 500 | Dengue Virus Infection | |
| NCT04023708 | Observational Study to Evaluate the Safety of CYD Tetravalent Dengue Vaccine (CYD-TDV) in Pregnant Women and Their Offsprings Inadvertently Exposed During Pregnancy | Completed | 2022-03-11 | 2023-03-27 | 104 | Dengue Virus Infection | |
| NCT04170140 | Study on Prescribers' Knowledge and Understanding of Safety Messages Following Dengvaxia® Product Information Update | Completed | 2020-01-07 | 2020-03-05 | 300 | Dengue Virus Infection | |
| NCT03960385 | Assessing the Effectiveness of Sanofi Pasteur's Dengue Vaccine (Dengvaxia) Against Hospitalization and Symptomatic Infection in the State of Parana - Brazil | Completed | 2017-08-01 | 2020-03-01 | 1854 | Dengue | |
| NCT02992418 | Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects | Terminated | Phase 3 | 2016-12-19 | 2019-12-10 | 688 | Dengue Fever; Dengue Hemorrhagic Fever |
| NCT02948933 | Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine | Completed | 2016-12-14 | 2022-12-22 | 30000 | Dengue Fever; Dengue Hemorrhagic Fever | |
| NCT02993757 | Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® | Completed | Phase 3 | 2016-12-01 | 2019-05-27 | 528 | Dengue Fever; Dengue Hemorrhagic Fever; Human Papillomavirus Disease |
| NCT02979535 | Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® | Completed | Phase 3 | 2016-11-16 | 2019-03-25 | 480 | Dengue Fever; Dengue Hemorrhagic Fever; Human Papillomavirus Disease |
| NCT00993447 | Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America | Completed | Phase 2 | 2009-10 | 2011-09 | 600 | Dengue; Dengue Fever; Dengue Hemorrhagic Fever; Dengue Virus |
| NCT00842530 | Efficacy and Safety of Dengue Vaccine in Healthy Children | Completed | Phase 2 | 2009-02 | 2013-09 | 4002 | Dengue Diseases; Dengue Fever; Dengue Hemorrhagic Fever; Dengue Virus |
Unconfirmed matches (1)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT03999996 | Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose | Completed | Phase 3 | 2019-11-12 | 2024-05-25 | 365 | Dengue Fever | name in intervention: Dengue Tetravalent Vaccine, Live |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41213642 | Safety and immunogenicity of a tetravalent dengue vaccine (CYD-TDV) in HIV-positive adults aged 18-50 years in Brazil: Results from a phase II, randomized, observer-blind, placebo-controlled trial. | Human vaccines & immunotherapeutics | 2025 | name in title: CYD-TDV |
| PMID 34635391 | Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand. | Human immunology | 2022 | name in abstract: CYD-TDV |
| PMID 35061851 | Pre-vaccination frequency of circulatory Tfh is associated with robust immune response to TV003 dengue vaccine. | PLoS pathogens | 2022 | name in abstract: CYD-TDV |
| PMID 35364022 | Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9-50 years: a randomised, controlled, phase 2, non-inferiority study. | The Lancet. Infectious diseases | 2022 | name in title: CYD-TDV |
| PMID 35505623 | A cross-sectional survey to evaluate prescribers' knowledge and understanding of safety messages following Dengvaxia® product information update. | Pharmacoepidemiology and drug safety | 2022 | cited by trial NCT04170140 |
| PMID 35659904 | Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with a new dengue rapid diagnostic test: a retrospective analysis of phase 3 efficacy trials. | The Lancet. Microbe | 2022 | name in abstract: CYD-TDV |
| PMID 36068106 | Neutralizing antibody correlates of sequence specific dengue disease in a tetravalent dengue vaccine efficacy trial in Asia. | Vaccine | 2022 | name in abstract: CYD-TDV |
| PMID 33212067 | Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study. | The Lancet. Infectious diseases | 2021 | name in title: CYD-TDV |
| PMID 33212068 | Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials. | The Lancet. Infectious diseases | 2021 | name in abstract: CYD-TDV |
| PMID 33369671 | Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries. | Transactions of the Royal Society of Tropical Medicine and Hygiene | 2021 | name in abstract: CYD-TDV |
| PMID 33626291 | Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial. | Human vaccines & immunotherapeutics | 2021 | name in abstract: CYD-TDV |
| PMID 33822015 | Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2021 | cited by trial NCT00842530 |
| PMID 33992441 | Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14 years in Mexico. | Vaccine | 2021 | cited by trial NCT02979535 |
| PMID 34003796 | Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection. | The Journal of clinical investigation | 2021 | name in abstract: Dengvaxia |
| PMID 34117198 | Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Tdap Vaccine: Randomized Phase IIIb Trial in Healthy Participants 9-60 Years of Age in the Philippines. | The Pediatric infectious disease journal | 2021 | cited by trial NCT02992418 |
| PMID 34250977 | Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Quadrivalent Human Papillomavirus Vaccine in Boys and Girls 9-13 Years of Age in Malaysia: A Phase IIIb, Randomized, Open-label Study. | The Pediatric infectious disease journal | 2021 | cited by trial NCT02993757 |
| PMID 34367162 | Adapting Rapid Diagnostic Tests to Detect Historical Dengue Virus Infections. | Frontiers in immunology | 2021 | name in abstract: Dengvaxia |
| PMID 31464558 | Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5-6 years after completion of the primary series. | Human vaccines & immunotherapeutics | 2020 | name in abstract: Dengvaxia |
| PMID 31755526 | The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Years in the United States. | The Journal of infectious diseases | 2020 | name in abstract: Dengvaxia |
| PMID 32040014 | Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia. | The Pediatric infectious disease journal | 2020 | name in abstract: CYD-TDV |
| PMID 32542024 | Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America. | PloS one | 2020 | name in title: CYD-TDV |
| PMID 32932330 | Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4-5 Years Earlier in Latin America: A Randomized Placebo-controlled Trial. | The Pediatric infectious disease journal | 2020 | cited by trial NCT00993447 |
| PMID 30724660 | Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials. | Human vaccines & immunotherapeutics | 2019 | name in title: CYD-TDV |
| PMID 30986790 | Dengue Vaccine Booster in Healthy Adolescents and Adults in Latin America: Evaluation 4-5 Years After a Primary 3-Dose Schedule. | The Pediatric infectious disease journal | 2019 | name in abstract: Dengvaxia |
| PMID 31115304 | Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response. | The American journal of tropical medicine and hygiene | 2019 | name in abstract: CYD-TDV |
| PMID 29194547 | Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America. | The Journal of infectious diseases | 2018 | name in abstract: CYD-TDV |
| PMID 29300876 | Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2018 | name in abstract: Dengvaxia |
| PMID 29573874 | A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia. | Vaccine | 2018 | name in title: Dengvaxia |
| PMID 29716774 | Dengue vaccination during pregnancy - An overview of clinical trials data. | Vaccine | 2018 | name in abstract: CYD-TDV |
| PMID 29897841 | Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. | The New England journal of medicine | 2018 | cited by trial NCT00842530 |
| PMID 30127007 | Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials. | Proceedings of the National Academy of Sciences of the United States of America | 2018 | name in abstract: CYD-TDV |
| PMID 30194294 | Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning. | Nature communications | 2018 | name in title: CYD-TDV |
| PMID 30241510 | Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults. | BMC infectious diseases | 2018 | name in abstract: CYD-TDV |
| PMID 30543657 | Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease. | PloS one | 2018 | name in abstract: CYD-TDV |
| PMID 27932620 | Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals. | The Journal of infectious diseases | 2017 | name in title: CYD-TDV |
| PMID 28067718 | Immunogenicity and Safety of a Booster Injection of DTap-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers 15-18 Months of Age in Mexico: A Randomized Trial. | The Pediatric infectious disease journal | 2017 | name in abstract: CYD-TDV |
| PMID 28968794 | Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding. | The Journal of infectious diseases | 2017 | name in title: CYD-TDV |
| PMID 29141713 | Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine. | The American journal of tropical medicine and hygiene | 2017 | name in abstract: CYD-TDV |
| PMID 26291554 | Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial. | Human vaccines & immunotherapeutics | 2016 | name in abstract: CYD-TDV |
| PMID 26836763 | A comparative study on active and passive epidemiological surveillance for dengue in five countries of Latin America. | International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2016 | name in abstract: CYD-TDV |
| PMID 27102820 | Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: Utility for efficacy evaluation and impact of future vaccine introduction. | Vaccine | 2016 | cited by trial NCT00842530 |
| PMID 27254034 | Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru: A Randomized Trial. | The Pediatric infectious disease journal | 2016 | name in abstract: CYD-TDV |
| PMID 27414655 | Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials. | PLoS neglected tropical diseases | 2016 | name in abstract: CYD-TDV |
| PMID 27459266 | Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials. | PLoS neglected tropical diseases | 2016 | name in abstract: CYD-TDV |
| PMID 25365753 | Efficacy of a tetravalent dengue vaccine in children in Latin America. | The New England journal of medicine | 2015 | name in abstract: CYD-TDV |
| PMID 25966916 | First Experience of Concomitant Vaccination Against Dengue and MMR in Toddlers. | The Pediatric infectious disease journal | 2015 | name in abstract: CYD-TDV |
| PMID 26214039 | Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. | The New England journal of medicine | 2015 | cited by trial NCT00842530 |
| PMID 26279339 | Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study. | Vaccine | 2015 | name in abstract: CYD-TDV |
| PMID 25018116 | Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. | Lancet (London, England) | 2014 | name in abstract: CYD-TDV |
| PMID 25483647 | Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico. | Human vaccines & immunotherapeutics | 2014 | name in abstract: CYD-TDV |
| PMID 23540847 | Efficacy of tetravalent dengue vaccine in Thai schoolchildren - Authors' reply. | Lancet (London, England) | 2013 | cited by trial NCT00842530 |
| PMID 23839107 | Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore. | Human vaccines & immunotherapeutics | 2013 | name in abstract: CYD-TDV |
| PMID 24021313 | Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA. | Vaccine | 2013 | name in abstract: CYD-TDV |
| PMID 24067553 | Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America. | The Pediatric infectious disease journal | 2013 | cited by trial NCT00993447 |
| PMID 24135573 | Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study. | Vaccine | 2013 | name in abstract: CYD-TDV |
| PMID 24189367 | Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil. | The American journal of tropical medicine and hygiene | 2013 | name in abstract: CYD-TDV |
| PMID 22863660 | Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. | Vaccine | 2012 | name in abstract: CYD-TDV |
| PMID 22894958 | Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore. | Human vaccines & immunotherapeutics | 2012 | name in title: CYD-TDV |
| PMID 22975340 | Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. | Lancet (London, England) | 2012 | cited by trial NCT00842530 |
Other papers
Preclinical studies, reviews and other papers that name it, newest 100 shown.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39871573 | Achievements and Approaches in the Search for Small-Molecule Dengue NS2B/NS3 Inhibitors. | Current medicinal chemistry | 2026 | name in abstract: Dengvaxia |
| PMID 40794141 | Dengue Vaccines. | Current topics in microbiology and immunology | 2026 | name in abstract: Dengvaxia |
| PMID 41201140 | Global epidemiology of dengue in paediatric and adolescent populations: a systematic review and meta-analysis. | Infectious diseases (London, England) | 2026 | name in abstract: CYD-TDV |
| PMID 41548813 | Animal models illuminate dengue immunopathogenesis to guide vaccine and therapeutic developments. | Journal of virological methods | 2026 | name in abstract: Dengvaxia |
| PMID 41557736 | Bridging the knowledge gap: Thai parents' perspectives on dengue infection and its vaccination and the need for targeted promotion. | PLoS neglected tropical diseases | 2026 | name in abstract: Dengvaxia |
| PMID 41577185 | Current status of dengue fever epidemics and vaccine development. | Virologica Sinica | 2026 | name in abstract: Dengvaxia |
| PMID 41579705 | Preclinical evaluation of DENV1 mRNA vaccines in mice: Toward improved neutralizing antibody and T cell responses. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 2026 | name in abstract: Dengvaxia |
| PMID 41619542 | Barriers to dengue vaccine coverage in low- and middle-income countries (LMICs). | Virology | 2026 | name in abstract: Dengvaxia |
| PMID 41662753 | Dengue Vaccine Effectiveness: Results from a 6-Year Population-Based Cohort Study in Southern Brazil. | The American journal of tropical medicine and hygiene | 2026 | name in abstract: Dengvaxia |
| PMID 41723069 | Adverse events following dengue vaccine (Dengvaxia) reported to the Vaccine Adverse Event Reporting System (VAERS), 2019-2025. | Vaccine | 2026 | name in title: Dengvaxia |
| PMID 41800104 | Post-marketing safety profile of dengue vaccines CYD-TDV and TAK-003: analysis of adverse event reports from a European database. | Frontiers in pharmacology | 2026 | name in title: CYD-TDV |
| PMID 41842965 | Safety of a tetravalent live dengue virus vaccine in children responding to one serotype only. | JCI insight | 2026 | name in abstract: Dengvaxia |
| PMID 41867205 | Inactivated Japanese encephalitis virus vaccination imprints fusion loop-biased antibody responses that are attenuated by repeated live-attenuated dengue vaccination. | medRxiv : the preprint server for health sciences | 2026 | name in abstract: CYD-TDV |
| PMID 41959375 | CD8+ T cells and Humoral Immunity Influence the Development of Antibody-Dependent Enhancement: Implications for Vaccine Design. | bioRxiv : the preprint server for biology | 2026 | name in abstract: Dengvaxia |
| PMID 42296464 | Dengue and chikungunya vaccines past, present and future: implications for travelers. | Current opinion in infectious diseases | 2026 | name in abstract: CYD-TDV |
| PMID 42507508 | Advanced next-generation vaccines for dengue and other flaviviral infections. | Journal of vector borne diseases | 2026 | name in abstract: Dengvaxia |
| PMID 42537921 | Neutralizing dengue antibodies after 10 years of the chimeric yellow fever tetravalent dengue vaccine (CYD-TDV) and dengue antibody cross-reactivity with SARS-CoV-2 in Indonesia. | Acta tropica | 2026 | name in title: CYD-TDV |
| PMID 42670066 | Prevention or Treatment of Dengue Virus Disease: An Update on Recent Vaccination and Therapeutics Globally. | Combinatorial chemistry & high throughput screening | 2026 | name in abstract: Dengvaxia |
| PMID 42713475 | Update on efficacy, safety, and immunogenicity of Dengue vaccines: a systematic review and meta-analysis. | Le infezioni in medicina | 2026 | name in abstract: Dengvaxia |
| PMID 42797550 | Dengue Vaccines in a Changing Epidemiological Landscape: Current Evidence, Unresolved Challenges, and Public Health Considerations. | Vaccines | 2026 | name in abstract: CYD-TDV |
| PMID 42854934 | An overview of current technologies in the development of drugs and vaccines against dengue virus. | Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases | 2026 | name in abstract: Dengvaxia |
| PMID 42925565 | Recent Landscape in Dengue Vaccines: A Systematic Review and Meta-Analysis. | Journal of vector borne diseases | 2026 | name in abstract: CYD-TDV |
| PMID 42927623 | Metabolic Screening and In Silico Investigation of Eucalyptus globulus Essential Oil Bioactives Against DENV-2 Envelope Protein. | ChemistryOpen | 2026 | name in abstract: Dengvaxia |
| PMID 42931365 | Efficacy, Immunogenicity, Safety, and Evidence Independence of CYD-TDV and TAK-003 Dengue Vaccines in Children and Adolescents: A Systematic Review and Meta-Analysis. | Vaccines | 2026 | name in title: CYD-TDV |
| PMID 42931431 | Immunological Challenges and Emerging Strategies in Dengue Virus Vaccine Development. | Vaccines | 2026 | name in abstract: Dengvaxia |
| PMID 42947633 | A Live Attenuated Dengue Virus Vaccine (Dengvaxia) is Suppressed in Individuals with Immunity to Serotype 4. | The Journal of infectious diseases | 2026 | name in title: Dengvaxia |
| PMID 42952807 | A single dose of Dengvaxia is associated with transient reduction in dengue infection risk among dengue-naïve children. | Frontiers in immunology | 2026 | name in title: Dengvaxia |
| PMID 42988214 | Real-world Evidence on dengue vaccine effectiveness: a systematic review of post-licensure evidence and methodological gaps. | International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2026 | name in abstract: CYD-TDV |
| PMID 42993603 | CD8+ T cells and humoral immunity may mitigate the effects of antibody-dependent enhancement: implications for dengue vaccine design. | Journal of virology | 2026 | name in abstract: Dengvaxia |
| PMID 39830640 | Current status of the development of dengue vaccines. | Vaccine: X | 2025 | name in abstract: Dengvaxia |
| PMID 39976669 | Nano-interventions for dengue: a comprehensive review of control, detection and treatment strategies. | Inflammopharmacology | 2025 | name in abstract: Dengvaxia |
| PMID 39995247 | Advances in the Epidemiology, Pathogenesis, Diagnostic Methods, and Vaccine Development of Dengue Fever: A Comprehensive Review. | Viral immunology | 2025 | name in abstract: Dengvaxia |
| PMID 40006692 | Dengue Vaccination: A Practical Guide for Clinicians. | Vaccines | 2025 | name in abstract: Dengvaxia |
| PMID 40014622 | Estimating per-infection cost and burden for dengue and Zika as a function of antibody-dependent enhancement. | PLoS neglected tropical diseases | 2025 | name in abstract: Dengvaxia |
| PMID 40044132 | Advancements in dengue vaccines: A historical overview and pro-spects for following next-generation candidates. | Journal of microbiology (Seoul, Korea) | 2025 | name in abstract: Dengvaxia |
| PMID 40109333 | Opportunities and challenges of mRNA technologies in development of dengue virus vaccine. | Frontiers in immunology | 2025 | name in abstract: Dengvaxia |
| PMID 40183845 | Impact of ADE and Dengue Vaccination with Screening on Cost and Disease Burden for Homoserotypic Dengue and Zika. | Bulletin of mathematical biology | 2025 | name in abstract: Dengvaxia |
| PMID 40195054 | Efficacy, Immune Response, and Safety of Dengue Vaccines in Adolescents: A Systematic Review. | Reviews in medical virology | 2025 | name in abstract: Dengvaxia |
| PMID 40252364 | Knowledge-based mitigation of the environmental risk of Orthoflavivirus live-attenuated vaccines by targeting viral encoded determinants for the mosquito attenuated phenotype. | Vaccine | 2025 | name in abstract: Dengvaxia |
| PMID 40266131 | The Genetic Evolution of DENV2 in the French Territories of the Americas: A Retrospective Study from the 2000s to the 2024 Epidemic, Including a Comparison of Amino Acid Changes with Vaccine Strains. | Vaccines | 2025 | name in abstract: Dengvaxia |
| PMID 40279922 | Effectiveness of a single-dose mass dengue vaccination in Cebu, Philippines: Final results of a 5-year case-control study. | Vaccine | 2025 | name in abstract: Dengvaxia |
| PMID 40339179 | Rebuilding Public Trust: Factors Influencing Dengue Vaccine Uptake in the Aftermath of the Dengvaxia Controversy in the Philippines: A Partial Least Structural Equation Modeling Approach. | Vaccine | 2025 | name in title: Dengvaxia |
| PMID 40432095 | Dengue Vaccine Development and Deployment into Routine Immunization. | Vaccines | 2025 | name in abstract: Dengvaxia |
| PMID 40432141 | Development of New Live-Attenuated Vaccine Candidates Lacking Antibody-Dependent Enhancement (ADE) Against Dengue. | Vaccines | 2025 | name in abstract: Dengvaxia |
| PMID 40669253 | From controversy to confidence: Strengthening dengue vaccines safety reporting. | Vaccine | 2025 | name in abstract: Dengvaxia |
| PMID 40734960 | Medical knowledge, political tension, and social relevance: a content and framing analysis of vaccine-related TV broadcasts in the Philippines. | BMJ public health | 2025 | name in abstract: Dengvaxia |
| PMID 40862147 | The pre- and post-COVID-19 pandemic dengue fever patterns in southeastern coastal China in 2019 and 2024: molecular evolution and strain replacement. | Frontiers in microbiology | 2025 | name in abstract: CYD-TDV |
| PMID 40969293 | Advancing dengue vaccine development: Challenges, innovations, and the path toward global protection. | Pediatric investigation | 2025 | name in abstract: CYD-TDV |
| PMID 40975348 | A retrospective computational validation of a clinically evaluated recombinant envelope protein tetravalent dengue vaccine. | International journal of biological macromolecules | 2025 | name in abstract: Dengvaxia |
| PMID 40981337 | State of the Art on Vaccine Development Against Dengue Infection: Scoping Review of the Literature. | Infectious disease reports | 2025 | name in abstract: Dengvaxia |
| PMID 40991727 | Afucosylation of anti-dengue IgG is associated with enhanced susceptibility to dengue virus infection postvaccination. | Science translational medicine | 2025 | name in abstract: Dengvaxia |
| PMID 41019525 | Pathophysiology and clinical implications of dengue-associated neurological disorders. | Frontiers in microbiology | 2025 | name in abstract: Dengvaxia |
| PMID 41034330 | Structural and energetic basis of marine phytochemicals as dengue NS1 protein inhibitors. | Scientific reports | 2025 | name in abstract: CYD-TDV |
| PMID 41086802 | Challenges in the Prevention and Treatment of Dengue Fever: An Emerging Issue. | The American journal of tropical medicine and hygiene | 2025 | name in abstract: Dengvaxia |
| PMID 41287091 | Dengue vaccine effectiveness and safety: a systematic analysis of recent clinical trial data. | Virology journal | 2025 | name in abstract: CYD-TDV |
| PMID 41295515 | Targeting Dendritic Cells with Virus-like Particles: Toward Safer and More Immunogenic Vaccines. | Vaccines | 2025 | name in abstract: Dengvaxia |
| PMID 41441649 | Optimizing Humoral Immunity for Durable and Broad Protection in Flavivirus Vaccines. | Vaccines | 2025 | name in abstract: CYD-TDV |
| PMID 37723635 | Development in the Inhibition of Dengue Proteases as Drug Targets. | Current medicinal chemistry | 2024 | name in abstract: Dengvaxia |
| PMID 37859315 | Computational Advancement towards the Identification of Natural Inhibitors for Dengue Virus: A Brief Review. | Combinatorial chemistry & high throughput screening | 2024 | name in abstract: Dengvaxia |
| PMID 37962048 | Exploring the Targets of Dengue Virus and Designs of Potential Inhibitors. | Combinatorial chemistry & high throughput screening | 2024 | name in abstract: Dengvaxia |
| PMID 38331225 | Potential of several triazene derivatives against DENGUE viruses. | Bioorganic & medicinal chemistry letters | 2024 | name in abstract: Dengvaxia |
| PMID 38350770 | Implications of information heard about Dengvaxia on Filipinos' perception on vaccination. | Vaccine | 2024 | name in title: Dengvaxia |
| PMID 38391779 | Dengue Fever Epidemics and the Prospect of Vaccines: A Systematic Review and Meta-Analysis Using Clinical Trials in Children. | Diseases (Basel, Switzerland) | 2024 | name in abstract: Dengvaxia |
| PMID 38527473 | Single dose of Dengvaxia vaccine: is it a cause for alarm? | The Lancet. Infectious diseases | 2024 | name in title: Dengvaxia |
| PMID 38527474 | Effect of single-dose, live, attenuated dengue vaccine in children with or without previous dengue on risk of subsequent, virologically confirmed dengue in Cebu, the Philippines: a longitudinal, prospective, population-based cohort study. | The Lancet. Infectious diseases | 2024 | name in abstract: CYD-TDV |
| PMID 38546211 | Exploring the therapeutic potential of DV-B-120 as an inhibitor of dengue virus infection. | Journal of virology | 2024 | name in abstract: Dengvaxia |
| PMID 38579018 | Use of Dengvaxia® in Australian travellers: a case series. | Journal of travel medicine | 2024 | name in title: Dengvaxia |
| PMID 38599678 | Perceptions of dengue risk and acceptability of a dengue vaccine in residents of Puerto Rico. | Human vaccines & immunotherapeutics | 2024 | name in abstract: Dengvaxia |
| PMID 38616437 | Super epitope dengue vaccine instigated serotype independent immune protection in-silico. | Vaccine | 2024 | name in abstract: Dengvaxia |
| PMID 38693800 | [Dengue vaccines, a time for cautious optimism?]. | Revue medicale suisse | 2024 | name in abstract: Dengvaxia |
| PMID 38712100 | Comparison of the Sensitivity and Specificity of Commercial Anti-Dengue Virus IgG Tests to Identify Persons Eligible for Dengue Vaccination. | medRxiv : the preprint server for health sciences | 2024 | name in abstract: Dengvaxia |
| PMID 38793612 | Regional Variation of the CD4 and CD8 T Cell Epitopes Conserved in Circulating Dengue Viruses and Shared with Potential Vaccine Candidates. | Viruses | 2024 | name in abstract: CYD-TDV |
| PMID 38807985 | Effectiveness of mass dengue vaccination with CYD-TDV (Dengvaxia®) in the state of Paraná, Brazil: integrating case-cohort and case-control designs. | Lancet regional health. Americas | 2024 | name in title: Dengvaxia |
| PMID 38845788 | Immunization against dengue virus infection is coercive: A timely call. | Health science reports | 2024 | name in abstract: Dengvaxia |
| PMID 39194193 | Comparison of the sensitivity and specificity of commercial anti-dengue virus IgG tests to identify persons eligible for dengue vaccination. | Journal of clinical microbiology | 2024 | name in abstract: Dengvaxia |
| PMID 39227968 | Trends and insights in dengue virus research globally: a bibliometric analysis (1995-2023). | Journal of translational medicine | 2024 | name in abstract: Dengvaxia |
| PMID 39228383 | An effective pan-serotype dengue vaccine and enhanced control strategies could help in reducing the severe dengue burden in Bangladesh-A perspective. | Frontiers in microbiology | 2024 | name in abstract: Dengvaxia |
| PMID 39336108 | An In Silico Design of a Vaccine against All Serotypes of the Dengue Virus Based on Virtual Screening of B-Cell and T-Cell Epitopes. | Biology | 2024 | name in abstract: Dengvaxia |
| PMID 39463237 | Vaccination against dengue fever for travellers. | Swiss medical weekly | 2024 | name in abstract: Dengvaxia |
| PMID 39543749 | Exploring plant-based dengue therapeutics: from laboratory to clinic. | Tropical diseases, travel medicine and vaccines | 2024 | name in abstract: Dengvaxia |
| PMID 39626875 | Dengue and severe dengue with neurological complications: a challenge for prevention and control. | Arquivos de neuro-psiquiatria | 2024 | name in abstract: Dengvaxia |
| PMID 39700304 | Genetic diversity of dengue virus circulating in the Philippines (2014-2019) and comparison with dengue vaccine strains. | PLoS neglected tropical diseases | 2024 | name in abstract: Dengvaxia |
| PMID 39776767 | Machine learning and molecular docking prediction of potential inhibitors against dengue virus. | Frontiers in chemistry | 2024 | name in abstract: Dengvaxia |
| PMID 40070980 | [Dengue fever vaccination Recommendations from the Société Francophone de Médecine Tropicale et de Santé Internationale for Metropolitan France and Overseas Territories]. | Medecine tropicale et sante internationale | 2024 | name in abstract: Dengvaxia |
| PMID 40093849 | Complexities of Dengue Fever: Pathogenesis, Clinical Features and Management Strategies. | Discoveries (Craiova, Romania) | 2024 | name in abstract: Dengvaxia |
| PMID 36300833 | Filipinos' COVID-19 vaccine hesitancy comments in TikTok videos: A manifest content analysis. | Public health nursing (Boston, Mass.) | 2023 | name in abstract: Dengvaxia |
| PMID 36417290 | Biologics for dengue prevention: up-to-date. | Expert opinion on biological therapy | 2023 | name in abstract: Dengvaxia |
| PMID 36801791 | Piperazine-derived small molecules as potential Flaviviridae NS3 protease inhibitors. In vitro antiviral activity evaluation against Zika and Dengue viruses. | Bioorganic chemistry | 2023 | name in abstract: Dengvaxia |
| PMID 36857199 | Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art. | The Journal of general virology | 2023 | name in abstract: Dengvaxia |
| PMID 36864886 | Assessing the potential of NS2B/NS3 protease inhibitors biomarker in curbing dengue virus infections: In silico vs. In vitro approach. | Frontiers in cellular and infection microbiology | 2023 | name in abstract: Dengvaxia |
| PMID 36914616 | A live dengue virus vaccine carrying a chimeric envelope glycoprotein elicits dual DENV2-DENV4 serotype-specific immunity. | Nature communications | 2023 | name in abstract: Dengvaxia |
| PMID 36992414 | Molecular Mechanisms of Antiviral Agents against Dengue Virus. | Viruses | 2023 | name in abstract: Dengvaxia |
| PMID 37114191 | A dengue vaccine whirlwind update. | Therapeutic advances in infectious disease | 2023 | name in abstract: Dengvaxia |
| PMID 37158835 | Comparing the performance of dengue virus IgG and IgG-capture enzyme-linked immunosorbent assays in seroprevalence study. | BMC infectious diseases | 2023 | name in abstract: Dengvaxia |
| PMID 37173267 | Dengue vaccine acceptability before and after the availability of COVID-19 vaccines in Puerto Rico. | Vaccine | 2023 | name in abstract: CYD-TDV |
| PMID 37192141 | Epidemiologic Trends of Dengue in U.S. Territories, 2010-2020. | Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002) | 2023 | name in abstract: Dengvaxia |
| PMID 37213267 | Identifying and Managing Vector-Borne Diseases in Migrants and Recent Travelers in the Emergency Department. | Current emergency and hospital medicine reports | 2023 | name in abstract: Dengvaxia |
| PMID 37251387 | Vaccine development for mosquito-borne viral diseases. | Frontiers in immunology | 2023 | name in abstract: CYD-TDV |
| PMID 37340460 | 'I was terrified for my child': understanding the link between the Dengvaxia® controversy and the measles vaccine hesitancy in Pasay City, Philippines. | Journal of public health (Oxford, England) | 2023 | name in title: Dengvaxia |
| PMID 37554332 | Identification of prior dengue-naïve Dengvaxia recipients with an increased risk for symptomatic dengue during fever surveillance in the Philippines. | Frontiers in immunology | 2023 | name in title: Dengvaxia |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| I01CX002688 | Durability and mechanisms of dengue vaccine and infection mediated immunity | ST. LOUIS VA MEDICAL CENTER | GEORGE, SARAH | 2024–2026 | name in abstract: Dengvaxia |
| P01AI106695 | Protective immunity following dengue virus natural infections and vaccination | UNIVERSITY OF CALIFORNIA BERKELEY | HARRIS, EVA | 2020–2026 | name in abstract: Dengvaxia |
| R01AI161025 | Structure based design of dengue subunit vaccines for inducing protective but not disease enhancing antibodies | UNIV OF NORTH CAROLINA CHAPEL HILL | DESILVA, ARAVINDA M. | 2022–2026 | name in project terms: Dengvaxia |
| R01AI170894 | A Novel T cell-based Vaccine to Prevent Dengue/Zika virus infection | GEORGIA STATE UNIVERSITY | QIAO, LIANG | 2025–2026 | name in abstract: Dengvaxia |
| R01AI175495 | Identification of serological markers of protection and risk for dengue vaccines and natural infection | JOHNS HOPKINS UNIVERSITY | CUMMINGS, DEREK A | 2023–2026 | name in project terms: Dengvaxia |
| R01AI179782 | Treating flaviviruses with mRNA-encoded Cas13 | EMORY UNIVERSITY | SANTANGELO, PHILIP J | 2024–2026 | name in abstract: Dengvaxia |
| R01AI186073 | Long-term safety and effectiveness of Dengvaxia in the Philippines | UNIVERSITY OF HAWAII AT MANOA | WANG, WEI-KUNG | 2024–2026 | name in title: Dengvaxia |
| R01AI192605 | Analysis of innate responses and vaccination-induced serotype-specific B and T cell responses associated with protection against controlled human dengue virus challenge | JOHNS HOPKINS UNIVERSITY | BAILEY, JUSTIN RICHARD | 2026–2026 | name in project terms: Dengvaxia |
| R01AI198147 | Mechanistic analysis of a combined liposome-TLR7/8-agonist adjuvanted virus-like particle vaccine | OREGON HEALTH & SCIENCE UNIVERSITY | HIRSCH, ALEC J | 2026–2026 | name in project terms: Dengvaxia |
| R01AI201550 | Past encounters, Future protection: Harnessing immune imprinting for improved vaccines | YALE UNIVERSITY | LUCAS, CAROLINA | 2026–2026 | name in project terms: Dengvaxia |
| R03AI193192 | Novel Antiviral Agents Targeting Zika and Dengue Virus | BAYLOR COLLEGE OF MEDICINE | LI, XIN | 2025–2026 | name in project terms: Dengvaxia |
| R21AI197057 | Qdenga Vaccine: Assessment of immunogenicity in a longitudinal cohort study | YALE UNIVERSITY | LUCAS, CAROLINA | 2026–2026 | name in project terms: Dengvaxia |
| R56AI150672 | Driving Protective Dengue Virus-Specific T and B Cell Responses Through Vaccination | UNIVERSITY OF ILLINOIS AT CHICAGO | RICHNER, JUSTIN | 2026–2026 | name in project terms: Dengvaxia |
| U01AI179523 | Long-term durability of DENV-specific immunity after vaccination in a dengue-endemic population | UNIVERSITY OF RHODE ISLAND | ROTHMAN, ALAN L | 2024–2026 | name in abstract: CYD-TDV |
| U01AI186860 | A Phase 2b randomized open label trial to assess the quality and balance of dengue immunity elicited by prime-boost combinations of TAK-003 and Butantan-DV | EMORY UNIVERSITY | COLLINS, MATTHEW | 2025–2026 | name in abstract: CYD-TDV |
| R01AI153500 | Maternal Antibody-Mediated Enhancement of Dengue Pathogenesis | LA JOLLA INSTITUTE FOR IMMUNOLOGY | SHRESTA, SUJAN | 2021–2025 | name in project terms: Dengvaxia |
| R01AI156187 | Probing Functional States and Inhibition of Flaviviral Proteases Using Nanopore Tweezers | UNIVERSITY OF MASSACHUSETTS AMHERST | CHEN, MIN | 2021–2025 | name in abstract: Dengvaxia |
| R01AI158194 | Structure-based design of broad flavivirus immunogens | ALBERT EINSTEIN COLLEGE OF MEDICINE | LAI, JONATHAN R. | 2021–2025 | name in project terms: Dengvaxia |
| R01AI163188 | Development of a Replicon RNA-based Vaccine against Dengue and Zika | LA JOLLA INSTITUTE FOR IMMUNOLOGY | SHRESTA, SUJAN | 2021–2025 | name in project terms: Dengvaxia |
| R44AI192180 | A Novel Cost-Effective Multispecific Therapeutic for Dengue | MAPP BIOPHARMACEUTICAL, INC. | ZEITLIN, LARRY | 2025–2025 | name in abstract: Dengvaxia |
| ZIAAI001346 | Immunology, virology, and epidemiology of flaviviruses and other emerging viruses | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES | KATZELNICK, LEAH | 2021–2025 | name in abstract: Dengvaxia |
| F30AI160898 | Age in dengue antibody response and risk after primary natural infection | UNIV OF NORTH CAROLINA CHAPEL HILL | ZHU, DEANNA | 2021–2024 | name in project terms: Dengvaxia |
| R01AI150672 | Dengue virus mRNA lipid nanoparticle vaccine | UNIVERSITY OF ILLINOIS AT CHICAGO | RICHNER, JUSTIN | 2021–2024 | name in abstract: Dengvaxia |
| R01AI157491 | Sex ratio distortion in Aedes aegypti | VIRGINIA POLYTECHNIC INST AND ST UNIV | TU, ZHIJIAN JAKE | 2020–2024 | name in abstract: Dengvaxia |
| R03AI171469 | An innovative and straightforward approach to construct and manipulate viral infectious clones | VIRGINIA POLYTECHNIC INST AND ST UNIV | WEGER, JAMES D | 2023–2024 | name in abstract: Dengvaxia |
| R21AI178617 | Immunogenicity of the dengue vaccine CYD-TDV in a dengue virus serotype 1 immune population | OREGON HEALTH & SCIENCE UNIVERSITY | MESSER, WILLIAM | 2023–2024 | name in title: CYD-TDV |
| U01AI134582 | A Phase II Evaluation of the Safety and Protective Efficacy of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV with Challenge by the Recombinant DENV-2 Virus in a Dengue Endemic Population | UNIVERSITY OF VERMONT & ST AGRIC COLLEGE | KIRKPATRICK, BETH DIANE | 2022–2024 | name in project terms: Dengvaxia |
| U19AI181960 | Core E: Correlates of Protection | WASHINGTON UNIVERSITY | DIAMOND, MICHAEL S | 2024–2024 | name in project terms: Dengvaxia |
| ZIAAI001167 | CAP:Evaluation of a Dengue Vaccine in Adults with Preexisting Flavivirus Immunity | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES | WHITEHEAD, STEPHEN | 2017–2024 | name in abstract: Dengvaxia |
| R21AI156059 | Role of nonstructural protein in limited genetic diversity of yellow fever 17D vaccine virus | UNIVERSITY OF TEXAS MED BR GALVESTON | BARRETT, ALAN D.T. | 2022–2023 | name in project terms: Dengvaxia |
| U01AI141997 | Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine | UNIVERSITY OF VERMONT & ST AGRIC COLLEGE | DIEHL, SEAN A. | 2021–2023 | name in project terms: Dengvaxia |
| U19AI111825 | Immunity to dengue viruses | ROCKEFELLER UNIVERSITY | WANG, TAIA | 2019–2023 | name in abstract: Dengvaxia |
| P01AI132132 | Zika virus pathophysiology during pregnancy | UNIVERSITY OF WISCONSIN-MADISON | O'CONNOR, DAVID H. | 2018–2022 | name in abstract: Dengvaxia |
| R01AI073755 | Antibody-based Protection against Flavivirses | WASHINGTON UNIVERSITY | DIAMOND, MICHAEL S | 2021–2022 | name in project terms: Dengvaxia |
| R01AI132563 | Previous exposure to dengue as a risk factor for Zika during pregnancy | UNIVERSITY OF MINNESOTA | ALIOTA, MATTHEW T | 2018–2022 | name in abstract: Dengvaxia |
| ZIAAI001347 | Epidemiology, immunology, and evolution of SARS-CoV-2 and other coronaviruses before and during the COVID-19 pandemic | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES | KATZELNICK, LEAH | 2021–2022 | name in abstract: Dengvaxia |
| R21AI148836 | Bacteriophage virus-like particle vaccines against dengue virus non-structural protein 1 | UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR | FRIETZE, KATHRYN M. | 2020–2021 | name in abstract: Dengvaxia |
| R43AI145617 | Discovery and Development of Broad-spectrum Protease Inhibitors of Flaviviruses of Significant Public Health Threats | PLEX PHARMACEUTICALS, INC. | REMACLE, ALBERT | 2021–2021 | name in project terms: Dengvaxia |
| R01AI125198 | PRECLINICAL ASSAYS TO PREDICT TETRAVALENT DENGUE VACCINE EFFICACY | UNIV OF NORTH CAROLINA CHAPEL HILL | DESILVA, ARAVINDA M. | 2016–2020 | name in abstract: CYD-TDV |
| R21AI145012 | The DKE-121 strain as a possible new Dengue virus serotype | WASHINGTON UNIVERSITY | DIAMOND, MICHAEL S | 2019–2020 | name in abstract: Dengvaxia |
| ZIAAI000987 | Clinical Trials of Biodefense Vaccines (Dengue) | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES | WHITEHEAD, STEPHEN | 2020–2020 | name in abstract: Dengvaxia |
| F31AI145408 | Computer-based Design of Dengue Virus Vaccine Antigens | UNIV OF NORTH CAROLINA CHAPEL HILL | KUDLACEK, STEPHAN | 2019–2019 | name in abstract: Dengvaxia |
| R21AI128681 | Rapid development and testing of Zika virus vaccine candidates | UNIVERSITY OF CONNECTICUT STORRS | VERARDI, PAULO H | 2016–2017 | name in abstract: Dengvaxia |
| R56AI132563 | Previous exposure to dengue as a risk factor for Zika virus during pregnancy | UNIVERSITY OF WISCONSIN-MADISON | ALIOTA, MATTHEW T | 2017–2017 | name in abstract: Dengvaxia |
Notes
Dengvaxia: four live chimeric viruses on the yellow fever 17D-204 backbone, each carrying the prM and E genes of one dengue serotype. Counted as a vector because the administered virus is YF 17D carrying foreign (dengue) antigens and the immunity sought is against dengue, not yellow fever. EU authorisation withdrawn at the holder's request on 2025-10-21; first approvals were in Mexico and other endemic countries from December 2015 (no agency record opened for those, so only the EMA and FDA rows are recorded). NCIt search for 'Dengvaxia' returned no concept.
How to cite
CYD-TDV (AXP000206.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000206.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.